TY - JOUR
T1 - Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes
AU - NIHR-BioResource Rare Diseases Consortium
AU - Whitworth, James
AU - Smith, Philip S.
AU - Martin, Jose Ezequiel
AU - West, Hannah
AU - Luchetti, Andrea
AU - Rodger, Faye
AU - Clark, Graeme
AU - Carss, Keren
AU - Stephens, Jonathan
AU - Stirrups, Kathleen
AU - Penkett, Chris
AU - Mapeta, Rutendo
AU - Ashford, Sofie
AU - Megy, Karyn
AU - Shakeel, Hassan
AU - Ahmed, Munaza
AU - Adlard, Julian
AU - Barwell, Julian
AU - Brewer, Carole
AU - Casey, Ruth T.
AU - Armstrong, Ruth
AU - Cole, Trevor
AU - Evans, Dafydd Gareth
AU - Fostira, Florentia
AU - Greenhalgh, Lynn
AU - Hanson, Helen
AU - Henderson, Alex
AU - Hoffman, Jonathan
AU - Izatt, Louise
AU - Kumar, Ajith
AU - Kwong, Ava
AU - Lalloo, Fiona
AU - Ong, Kai Ren
AU - Paterson, Joan
AU - Park, Soo Mi
AU - Chen-Shtoyerman, Rakefet
AU - Searle, Claire
AU - Side, Lucy
AU - Skytte, Anne Bine
AU - Snape, Katie
AU - Woodward, Emma R.
AU - Aitman, Timothy
AU - Alachkar, Hana
AU - Ali, Sonia
AU - Allen, Louise
AU - Allsup, David
AU - Ambegaonkar, Gautum
AU - Anderson, Julie
AU - Antrobus, Richard
AU - Armstrong, Ruth
AU - Arno, Gavin
AU - Arumugakani, Gururaj
AU - Ashford, Sofie
AU - Astle, William
AU - Attwood, Antony
AU - Austin, Steve
AU - Bacchelli, Chiara
AU - Bakchoul, Tamam
AU - Bariana, Tadbir K.
AU - Baxendale, Helen
AU - Bennett, David
AU - Bethune, Claire
AU - Bibi, Shahnaz
AU - Bitner-Glindzicz, Maria
AU - Bleda, Marta
AU - Boggard, Harm
AU - Bolton-Maggs, Paula
AU - Booth, Claire
AU - Bradley, John R.
AU - Brady, Angie
AU - Brown, Matthew
AU - Browning, Michael
AU - Bryson, Christine
AU - Burns, Siobhan
AU - Calleja, Paul
AU - Canham, Natalie
AU - Carmichael, Jenny
AU - Carss, Keren
AU - Caulfield, Mark
AU - Chalmers, Elizabeth
AU - Chandra, Anita
AU - Chinnery, Patrick
AU - Chitre, Manali
AU - Church, Colin
AU - Clement, Emma
AU - Clements-Brod, Naomi
AU - Clowes, Virginia
AU - Coghlan, Gerry
AU - Collins, Peter
AU - Cookson, Victoria
AU - Cooper, Nichola
AU - Corris, Paul
AU - Creaser-Myers, Amanda
AU - DaCosta, Rosa
AU - Daugherty, Louise
AU - Davies, Sophie
AU - Davis, John
AU - De Vries, Minka
AU - Deegan, Patrick
AU - Deevi, Sri V.V.
AU - Deshpande, Charu
AU - Devlin, Lisa
AU - Dewhurst, Eleanor
AU - Dixon, Peter
AU - Doffinger, Rainer
AU - Dormand, Natalie
AU - Drewe, Elizabeth
AU - Edgar, David
AU - Egner, William
AU - Erber, Wendy N.
AU - Erwood, Marie
AU - Everington, Tamara
AU - Favier, Remi
AU - Firth, Helen
AU - Fletcher, Debra
AU - Flinter, Frances
AU - Frary, Amy
AU - Freson, Kathleen
AU - Furie, Bruce
AU - Furnell, Abigail
AU - Gale, Daniel
AU - Gardham, Alice
AU - Gattens, Michael
AU - Ghali, Neeti
AU - Ghataorhe, Pavandeep K.
AU - Ghurye, Rohit
AU - Gibbs, Simon
AU - Gilmour, Kimberley
AU - Gissen, Paul
AU - Goddard, Sarah
AU - Gomez, Keith
AU - Gordins, Pavel
AU - Gräf, Stefan
AU - Gräf, Stefan
AU - Greene, Daniel
AU - Greenhalgh, Alan
AU - Greinacher, Andreas
AU - Grigoriadou, Sofia
AU - Grozeva, Detelina
AU - Hackett, Scott
AU - Hadinnapola, Charaka
AU - Hague, Rosie
AU - Haimel, Matthias
AU - Halmagyi, Csaba
AU - Hammerton, Tracey
AU - Hart, Daniel
AU - Hayman, Grant
AU - Heemskerk, Johan W.M.
AU - Henderson, Robert
AU - Hensiek, Anke
AU - Henskens, Yvonne
AU - Herwadkar, Archana
AU - Holden, Simon
AU - Holder, Muriel
AU - Holder, Susan
AU - Hu, Fengyuan
AU - Huis in't Veld, Anna
AU - Huissoon, Aarnoud
AU - Humbert, Marc
AU - Hurst, Jane
AU - James, Roger
AU - Jolles, Stephen
AU - Josifova, Dragana
AU - Kazmi, Rashid
AU - Keeling, David
AU - Kelleher, Peter
AU - Kelly, Anne M.
AU - Kennedy, Fiona
AU - Kiely, David
AU - Kingston, Nathalie
AU - Koziell, Ania
AU - Krishnakumar, Deepa
AU - Kuijpers, Taco
AU - Kuijpers, Taco
AU - Kumararatne, Dinakantha
AU - Kurian, Manju
AU - Laffan, Michael A.
AU - Lambert, Michele P.
AU - Allen, Hana Lango
AU - Lango-Allen, Hana
AU - Lawrie, Allan
AU - Lear, Sara
AU - Lees, Melissa
AU - Lentaigne, Claire
AU - Liesner, Ri
AU - Linger, Rachel
AU - Longhurst, Hilary
AU - Lorenzo, Lorena
AU - Louka, Eleni
AU - Machado, Rajiv
AU - Ross, Rob Mackenzie
AU - MacLaren, Robert
AU - Maher, Eamonn
AU - Maimaris, Jesmeen
AU - Mangles, Sarah
AU - Manson, Ania
AU - Mapeta, Rutendo
AU - Markus, Hugh S.
AU - Martin, Jennifer
AU - Masati, Larahmie
AU - Mathias, Mary
AU - Matser, Vera
AU - Maw, Anna
AU - McDermott, Elizabeth
AU - McJannet, Coleen
AU - Meacham, Stuart
AU - Meehan, Sharon
AU - Megy, Karyn
AU - Mehta, Sarju
AU - Michaelides, Michel
AU - Millar, Carolyn M.
AU - Moledina, Shahin
AU - Moore, Anthony
AU - Morrell, Nicholas
AU - Mumford, Andrew
AU - Murng, Sai
AU - Murphy, Elaine
AU - Nejentsev, Sergey
AU - Noorani, Sadia
AU - Nurden, Paquita
AU - Oksenhendler, Eric
AU - Othman, Shokri
AU - Ouwehand, Willem H.
AU - Papadia, Sofia
AU - Park, Soo Mi
AU - Parker, Alasdair
AU - Pasi, John
AU - Patch, Chris
AU - Paterson, Joan
AU - Payne, Jeanette
AU - Peacock, Andrew
AU - Peerlinck, Kathelijne
AU - Penkett, Christopher J.
AU - Pepke-Zaba, Joanna
AU - Perry, David
AU - Perry, David J.
AU - Pollock, Val
AU - Polwarth, Gary
AU - Ponsford, Mark
AU - Qasim, Waseem
AU - Quinti, Isabella
AU - Rankin, Stuart
AU - Rankin, Julia
AU - Raymond, F. Lucy
AU - Rayner-Matthews, Paula
AU - Rehnstrom, Karola
AU - Reid, Evan
AU - Rhodes, Christopher J.
AU - Richards, Michael
AU - Richardson, Sylvia
PY - 2018/7/5
Y1 - 2018/7/5
N2 - Multiple primary tumors (MPTs) affect a substantial proportion of cancer survivors and can result from various causes, including inherited predisposition. Currently, germline genetic testing of MPT-affected individuals for variants in cancer-predisposition genes (CPGs) is mostly targeted by tumor type. We ascertained pre-assessed MPT individuals (with at least two primary tumors by age 60 years or at least three by 70 years) from genetics centers and performed whole-genome sequencing (WGS) on 460 individuals from 440 families. Despite previous negative genetic assessment and molecular investigations, pathogenic variants in moderate- and high-risk CPGs were detected in 67/440 (15.2%) probands. WGS detected variants that would not be (or were not) detected by targeted resequencing strategies, including low-frequency structural variants (6/440 [1.4%] probands). In most individuals with a germline variant assessed as pathogenic or likely pathogenic (P/LP), at least one of their tumor types was characteristic of variants in the relevant CPG. However, in 29 probands (42.2% of those with a P/LP variant), the tumor phenotype appeared discordant. The frequency of individuals with truncating or splice-site CPG variants and at least one discordant tumor type was significantly higher than in a control population (χ2 = 43.642; p ≤ 0.0001). 2/67 (3%) probands with P/LP variants had evidence of multiple inherited neoplasia allele syndrome (MINAS) with deleterious variants in two CPGs. Together with variant detection rates from a previous series of similarly ascertained MPT-affected individuals, the present results suggest that first-line comprehensive CPG analysis in an MPT cohort referred to clinical genetics services would detect a deleterious variant in about a third of individuals.
AB - Multiple primary tumors (MPTs) affect a substantial proportion of cancer survivors and can result from various causes, including inherited predisposition. Currently, germline genetic testing of MPT-affected individuals for variants in cancer-predisposition genes (CPGs) is mostly targeted by tumor type. We ascertained pre-assessed MPT individuals (with at least two primary tumors by age 60 years or at least three by 70 years) from genetics centers and performed whole-genome sequencing (WGS) on 460 individuals from 440 families. Despite previous negative genetic assessment and molecular investigations, pathogenic variants in moderate- and high-risk CPGs were detected in 67/440 (15.2%) probands. WGS detected variants that would not be (or were not) detected by targeted resequencing strategies, including low-frequency structural variants (6/440 [1.4%] probands). In most individuals with a germline variant assessed as pathogenic or likely pathogenic (P/LP), at least one of their tumor types was characteristic of variants in the relevant CPG. However, in 29 probands (42.2% of those with a P/LP variant), the tumor phenotype appeared discordant. The frequency of individuals with truncating or splice-site CPG variants and at least one discordant tumor type was significantly higher than in a control population (χ2 = 43.642; p ≤ 0.0001). 2/67 (3%) probands with P/LP variants had evidence of multiple inherited neoplasia allele syndrome (MINAS) with deleterious variants in two CPGs. Together with variant detection rates from a previous series of similarly ascertained MPT-affected individuals, the present results suggest that first-line comprehensive CPG analysis in an MPT cohort referred to clinical genetics services would detect a deleterious variant in about a third of individuals.
KW - cancer-predisposition syndromes
KW - genetic testing
KW - inherited cancer genetics
KW - whole-genome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85048339749&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2018.04.013
DO - 10.1016/j.ajhg.2018.04.013
M3 - Article
C2 - 29909963
AN - SCOPUS:85048339749
SN - 0002-9297
VL - 103
SP - 3
EP - 18
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 1
ER -